Nothing Special   »   [go: up one dir, main page]

CA2374198A1 - Therapie combinee pour le traitement des infections dues au vif - Google Patents

Therapie combinee pour le traitement des infections dues au vif Download PDF

Info

Publication number
CA2374198A1
CA2374198A1 CA002374198A CA2374198A CA2374198A1 CA 2374198 A1 CA2374198 A1 CA 2374198A1 CA 002374198 A CA002374198 A CA 002374198A CA 2374198 A CA2374198 A CA 2374198A CA 2374198 A1 CA2374198 A1 CA 2374198A1
Authority
CA
Canada
Prior art keywords
fiv
azt
cats
nucleoside analog
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002374198A
Other languages
English (en)
Inventor
Maki Arai
Janet K. Yamamoto
Ben M. Dunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2374198A1 publication Critical patent/CA2374198A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des procédés de traitements thérapeutiques et prophylactiques des infections des chats par le VIF recourant à une combinaison de composés antirétroviraux. Dans une exécution le procédé consiste à administrer à un animal une dose efficace d'AZT et d'un autre analogue de glucoside tel que par exemple du 3TC; dans une autre exécution on administre aux chats une ou des doses efficaces d'AZT, de 3TC et d'un inhibiteur de protéase rétrovirale.
CA002374198A 1998-05-29 1999-05-28 Therapie combinee pour le traitement des infections dues au vif Abandoned CA2374198A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8728198P 1998-05-29 1998-05-29
US60/087,281 1998-05-29
PCT/US1999/011940 WO1999060988A2 (fr) 1998-05-29 1999-05-28 Therapie combinee pour le traitement des infections dues au vif

Publications (1)

Publication Number Publication Date
CA2374198A1 true CA2374198A1 (fr) 1999-12-02

Family

ID=22204237

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002374198A Abandoned CA2374198A1 (fr) 1998-05-29 1999-05-28 Therapie combinee pour le traitement des infections dues au vif

Country Status (4)

Country Link
EP (1) EP1146882A2 (fr)
AU (1) AU4219799A (fr)
CA (1) CA2374198A1 (fr)
WO (1) WO1999060988A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067984A2 (fr) 2001-02-22 2002-09-06 University Of Florida Materiaux et methodes permettant de detecter, de prevenir et de traiter une infection retrovirale a vih ou a vif
US9298887B2 (en) * 2011-07-13 2016-03-29 White Cell Rx Holdings Pty Ltd Medication management system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6689761B1 (en) * 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
AU6676796A (en) * 1995-07-13 1997-02-10 Sloan-Kettering Institute For Cancer Research Compounds, compositions, and methods for inhibiting replication of retroviruses and for inhibiting tumor promoter initiated transcription
CO4900074A1 (es) * 1996-06-25 2000-03-27 Glaxo Group Ltd Combinaciones antivirales
DE19703131A1 (de) * 1997-01-29 1998-07-30 Bayer Ag Verwendung von Chinoxalin in Dreier-Kombination mit Protease-Inhibitoren und Reverse Transkriptaseinhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
JP2002518452A (ja) * 1998-06-24 2002-06-25 エモリ ユニバーシティ Ｈｉｖの治療薬物の製造のための他の抗ｈｉｖ薬と組み合わせた３’−アジド−２’，３’−ジデオキシウリジンの使用

Also Published As

Publication number Publication date
WO1999060988A3 (fr) 2000-12-07
EP1146882A2 (fr) 2001-10-24
WO1999060988A9 (fr) 2000-02-24
WO1999060988A2 (fr) 1999-12-02
AU4219799A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
De Clercq Antiviral therapy for human immunodeficiency virus infections
Reeves et al. Emerging drug targets for antiretroviral therapy
Clercq New anti‐HIV agents and targets
Broder et al. Antiretroviral therapy in AIDS
Richman Zidovudine resistance of human immunodeficiency virus
Van Rompay Evaluation of antiretrovirals in animal models of HIV infection
Pereira et al. Anti-HIV drug development-an overview
Arai et al. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis?
Naesens et al. 9-(2-Phosphonylmethoxyethyl)-2, 6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo
Sina et al. Coreceptor use in nonhuman primate models of HIV infection
TURANO et al. Inhibitory effect of papaverine on HIV replication in vitro
HARA et al. Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents
Schols et al. Differential activity of polyanionic compounds and castanospermine against HIV replication and HIV-induced syncytium formation depending on virus strain and cell type
Connolly et al. Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition
Tanabe-Tochikura et al. Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro
Saksena et al. Viral reservoirs an impediment to HAART: new strategies to eliminate HIV-1
US6875773B1 (en) Combination therapy for treatment of FIV infection
De Clercq New anti-HIV agents in preclinical or clinical development
CA2374198A1 (fr) Therapie combinee pour le traitement des infections dues au vif
Vogt et al. Prospects for the prevention and therapy of infections with the human immunodeficiency virus
Alfano et al. The HIV life cycle: Multiple targets for antiretroviral agents
Wainberg et al. Vaccine and antiviral strategies against infections caused by human immunodeficiency virus.
US20090197827A1 (en) Combination Therapy for Treatment of FIV Infection
Polsky Antiviral chemotherapy for infection with human immunodeficiency virus
Wainberg et al. Strategies in the Treatment of AIDS and Related Diseases: The Lessons of Cancer Chemotherapy: New Drugs

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead